{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:04:56Z","timestamp":1788206696843,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> The aim of this study was to explore the respective use of angiotensin-converting-enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) on the outcomes of patients who could be weaned from dialysis-requiring acute kidney injury (AKI-D).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This case\u2013control study enrolled 41,731 patients who were weaned from AKI-D for at least 7\u00a0days from Taiwan\u2019s National Health Insurance Administration. We further grouped AKI-D patients according to ACEi and ARB use to evaluate subsequent risks of all-cause mortality and re-dialysis. The outcomes included the all-cause mortality and new-onset of end-stage kidney disease (ESKD; re-dialysis) following withdraw from AKI-D.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 17,141 (41.1%) patients surviving AKI-D could be weaned from dialysis for at least 7\u00a0days. The overall events of mortality were 366 (48.9%) in ACEi users, 659 (52.1%) in ARB users, and 6,261 (41.3%) in ACEi\/ARB nonusers, during a mean follow-up period of 1.01\u00a0years after weaning from AKI-D. In regard to all-cause of mortality, pre-dialysis ARB users had lower incidence than ACEi users [hazard ratio (HR 0.82), <jats:italic>p<\/jats:italic> = 0.017]. Compared with ACEi\/ARB nonusers, continuing ARB users had a significantly low risk of long-term all-cause mortality (adjusted hazard ratio 0.51, <jats:italic>p<\/jats:italic> = 0.013) after propensity score matching. However, new users of ACEi at the acute kidney disease (AKD) period had a higher risk of re-dialysis after weaning than ACEi\/ARB nonusers (aHR 1.82, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), whereas neither ACEi nor ARB users confronted significantly increased risks of hyperkalemia after weaning.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Compared with patients without ACEi\/ARB, those continuing to use ARB before the event and after weaning had low all-cause mortality, while new users of ACEi at AKD had increased risk of re-dialysis. AKI-D patients continuing to use ACEi or ARB did not have higher risk of hyperkalemia. Future prospective randomized trials are expected to confirm these findings.<\/jats:p>","DOI":"10.3389\/fphar.2022.714658","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T06:16:02Z","timestamp":1650435362000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Angiotensin II Receptor Blocker Associated With Less Outcome Risk in Patients With Acute Kidney Disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Vin-Cent","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Chi","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kuan","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hao","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S","family":"Chueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2215\/CJN.05271107","article-title":"Preoperative Use of Angiotensin-Converting Enzyme Inhibitors\/angiotensin Receptor Blockers Is Associated with Increased Risk for Acute Kidney Injury after Cardiovascular Surgery","volume":"3","author":"Arora","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/circulationaha.115.017719","article-title":"Introduction to the Analysis of Survival Data in the Presence of Competing Risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamainternmed.2018.4749","article-title":"Chronic Disease: Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with Outcomes after Acute Kidney Injury","volume":"178","author":"Brar","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"c305","DOI":"10.1159\/000321171","article-title":"Prevalence of Acute Kidney Injury Following Cardiac Surgery and Related Risk Factors in Chinese Patients","volume":"117","author":"Che","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/ndt\/gft405","article-title":"Preoperative Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blocker Use and Acute Kidney Injury in Patients Undergoing Cardiac Surgery","volume":"28","author":"Coca","year":"2013","journal-title":"Nephrol. Dial. Transpl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/bcp.12419","article-title":"Antihypertensive Agents Acting on the Renin-Angiotensin System and the Risk of Sepsis","volume":"78","author":"Dial","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can Angiotensin Receptor-Blocking Drugs Perhaps Be Harmful in the COVID-19 Pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J. Hypertens."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12882-015-0162-x","article-title":"Angiotensin Converting Enzyme Inhibition Increases ADMA Concentration in Patients on Maintenance Hemodialysis-Aa Randomized Cross-Over Study","volume":"16","author":"Gamboa","year":"2015","journal-title":"BMC Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1681\/ASN.2011030287","article-title":"Comparative Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin-Receptor Blockade on Inflammation during Hemodialysis","volume":"23","author":"Gamboa","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1113\/expphysiol.2007.041855","article-title":"Differential Regulation of Renal Angiotensin-Converting Enzyme (ACE) and ACE2 during ACE Inhibition and Dietary Sodium Restriction in Healthy Rats","volume":"93","author":"Hamming","year":"2008","journal-title":"Exp. Physiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2021.5151","article-title":"Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review","volume":"1","author":"Khan","year":"2022","journal-title":"JAMA Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"Improving Global Outcomes Diabetes Work: KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"98","author":"Kidney Disease","year":"2020","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/s41598-020-58705-0","article-title":"Comparative Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Coronary Artery Bypass Grafting","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1097\/CCM.0000000000003475","article-title":"Chen and on the Behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases: Risk of Sepsis and Mortality Among Patients with Chronic Obstructive Pulmonary Disease Treated with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers","volume":"47","author":"Lai","year":"2019","journal-title":"Crit. Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0189126","DOI":"10.1371\/journal.pone.0189126","article-title":"Angiotensin Receptor Blockers Are Associated with Lower Mortality Than ACE Inhibitors in Predialytic Stage 5 Chronic Kidney Disease: A Nationwide Study of Therapy with Renin-Angiotensin System Blockade","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ekir.2020.07.031","article-title":"Quality of Care for Acute Kidney Disease: Current Knowledge Gaps and Future Directions","volume":"5","author":"Liu","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1536\/ihj.50.501","article-title":"Effects of ARB or ACE-Inhibitor Administration on Plasma Levels of Aldosterone and Adiponectin in Hypertension","volume":"50","author":"Nakamura","year":"2009","journal-title":"Int. Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.kint.2020.04.020","article-title":"Controversies in Acute Kidney Injury: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"98","author":"Ostermann","year":"2020","journal-title":"Kidney Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2019209","DOI":"10.1001\/jamanetworkopen.2020.19209","article-title":"Recommendations on Acute Kidney Injury Biomarkers from the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement","volume":"3","author":"Ostermann","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bcp.13449","article-title":"Drug Management in Acute Kidney Disease - Report of the Acute Disease Quality Initiative XVI Meeting","volume":"84","author":"Ostermann","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/heartjnl-2016-310705","article-title":"Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in High Vascular Risk","volume":"103","author":"Potier","year":"2017","journal-title":"Heart"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of Angiotensin-Converting Enzyme (ACE), its Homologue ACE2 and Neprilysin in Angiotensin Peptide Metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"26335","DOI":"10.1038\/srep26335","article-title":"Urinary \u03c0-glutathione S-Transferase Predicts Advanced Acute Kidney Injury Following Cardiovascular Surgery","volume":"6","author":"Shu","year":"2016","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, Angiotensin-(1-7) and Mas Receptor axis in Inflammation and Fibrosis","volume":"169","author":"Simoes e Silva","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/nep.12284","article-title":"Angiotensin-converting Enzyme Inhibitor Usage and Acute Kidney Injury: a Secondary Analysis of RENAL Study Outcomes","volume":"19","author":"Wang","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MNH.0000000000000378","article-title":"Angiotensin-converting Enzyme 2 and Renal Disease","volume":"27","author":"Williams","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cpt.173","article-title":"Pentoxifylline Decreases Dialysis Risk in Patients with Advanced Chronic Kidney Disease","volume":"98","author":"Wu","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1185","DOI":"10.1097\/CCM.0000000000004588","article-title":"Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term Outcomes in Postacute Kidney Injury Patients with Hypertension*","volume":"48","author":"Yang","year":"2020","journal-title":"Crit. Care Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.714658\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T06:16:05Z","timestamp":1650435365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.714658\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":34,"alternative-id":["10.3389\/fphar.2022.714658"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.714658","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"article-number":"714658"}}